WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
* Anticipates a six-month FDA review timeline with potential for approval and launch in Q4 of 2017 * Amag Pharmaceuticals - if makena auto-injector is approved, Amag will request orange book listing ...
“While total Makena revenues in the first quarter were adversely impacted by a number of non-recurring charges, we are encouraged by the strong underlying demand for the subcutaneous auto-injector, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results